Immunome, Inc. (NASDAQ:IMNM) CTO Acquires $198,030.00 in Stock

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) CTO Philip Tsai bought 21,000 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the purchase, the chief technology officer now directly owns 21,000 shares in the company, valued at $198,030. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Immunome Stock Up 13.5 %

Shares of IMNM traded up $1.33 during midday trading on Monday, reaching $11.15. 2,245,245 shares of the stock were exchanged, compared to its average volume of 779,781. The stock's 50 day simple moving average is $12.49 and its 200 day simple moving average is $13.55. The company has a market cap of $695.98 million, a P/E ratio of -1.37 and a beta of 1.82. Immunome, Inc. has a twelve month low of $6.93 and a twelve month high of $30.96.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on IMNM shares. Stephens initiated coverage on Immunome in a research note on Friday, November 8th. They issued an "overweight" rating and a $30.00 price target on the stock. Piper Sandler dropped their price objective on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Thursday, November 14th. Finally, Wedbush reaffirmed an "outperform" rating and set a $33.00 target price on shares of Immunome in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome currently has an average rating of "Buy" and a consensus price target of $28.83.

Institutional Trading of Immunome

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Sofinnova Investments Inc. grew its position in shares of Immunome by 10.3% during the 2nd quarter. Sofinnova Investments Inc. now owns 655,680 shares of the company's stock worth $7,934,000 after purchasing an additional 61,284 shares in the last quarter. Cetera Investment Advisers acquired a new stake in Immunome during the first quarter worth approximately $3,038,000. Victory Capital Management Inc. grew its position in Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company's stock worth $10,684,000 after buying an additional 237,497 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Immunome by 113.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company's stock worth $55,425,000 after acquiring an additional 1,194,451 shares during the period. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Immunome during the 2nd quarter valued at $1,379,000. Institutional investors and hedge funds own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.